Hi BPP , Guggsy and co. In my humble opinion, having had a read through the report and financials, All of that market penetration will be required for this company to be profitable. At current rate, and looking forward with more sales people required to break into foreign markets, there is a long way to go before sales cover company costs ( remuneration in particular) which are bleeding cash at an alarming rate - and then turn a profit reflective of MC.
It can be done ( I certainly hope so ) but it is not a fait accomplie . The figures are not particularly pretty for this far in. And yes I am holding for longer, but the next set of figures would want to show a marked improvement . Paint it any way you wish,
BTW, does anyone else find it disturbing that so much ink is used "justifying" the remuneration packages based on comparisons with companies of similar market capitalization ? How many of those are established bedded down and offering a reasonable real value per share for their investors.
Restraint until the runs are on the board please ( meaning a profitable business).
cheers and good luck to all.
- Forums
- ASX - By Stock
- PCK
- PainChek General Discussion
PainChek General Discussion, page-17147
-
- There are more pages in this discussion • 3,266 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PCK (ASX) to my watchlist
|
|||||
Last
2.8¢ |
Change
-0.002(6.67%) |
Mkt cap ! $45.80M |
Open | High | Low | Value | Volume |
2.9¢ | 3.0¢ | 2.8¢ | $15.39K | 528.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 1693060 | 2.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.9¢ | 293045 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 1683060 | 0.028 |
8 | 1053639 | 0.027 |
4 | 385422 | 0.026 |
4 | 3079000 | 0.025 |
1 | 125040 | 0.024 |
Price($) | Vol. | No. |
---|---|---|
0.029 | 293045 | 1 |
0.030 | 1189635 | 2 |
0.032 | 24900 | 1 |
0.033 | 410208 | 3 |
0.034 | 5874 | 1 |
Last trade - 15.43pm 15/07/2024 (20 minute delay) ? |
Featured News
PCK (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online